- Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
- Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
- Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
- Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
- Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Castle Biosciences Announces Updates to its Board of Directors
- Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
- Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
- Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
- New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
More ▼
Key statistics
On Tuesday, Castle Biosciences Inc (CSTL:NMQ) closed at 20.06, -24.87% below its 52-week high of 26.70, set on May 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.61 |
---|---|
High | 20.67 |
Low | 19.61 |
Bid | 17.32 |
Offer | 21.93 |
Previous close | 19.61 |
Average volume | 125.90k |
---|---|
Shares outstanding | 27.59m |
Free float | 26.41m |
P/E (TTM) | -- |
Market cap | 540.98m USD |
EPS (TTM) | -2.15 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 21:00 BST.
More ▼